Articles tagged with Metastasis
Researchers propose a new method of clustering colorectal cancer patients using differential presence of exons (DPE) sequencing, which can provide valuable information on CRC progression and response to therapy. This analysis may also reduce costs and time required for staging CRC patients.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
Researchers used microfluidic devices to track what happens to cancer cells as they migrate and take root in the brain. They found that Dkk-1 triggers cancer cell migration, and reducing its levels near tumor cells may disrupt crosstalk between brain niche cells and cancer cells.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
A team of scientists at Memorial Sloan Kettering Cancer Center identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors. Drugs that activate STING could help prevent the spread of cancer to new sites, a process known as metastasis.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
The circadian rhythm governs most cellular functions implicated in cancer progression, making it an opportunity to intervene in the most timely and effective way. Leveraging this information, chronotherapy holds promise as a valuable alternative treatment option.
Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.
A recent study analyzed 7,301 metastatic breast cancer patients with MTAP loss, revealing younger age, higher TNBC cases, and BRCA1 mutations. The findings also suggest potential therapeutic agents targeting PRMT5 and MTA2 in MTAP-deficient cancers.
Researchers at City University of Hong Kong identified lysyl hydroxylase 1 (LH1) as a key factor in promoting confined migration of liver and pancreatic cancer cells. The study found that LH1 promotes metastasis by stabilizing Septin2, which enhances the actin network.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
Researchers identified a way to treat surrounding breast tumors that have spread to bone, making them vulnerable to the immune system's attack. Boosting T cells and macrophages eliminated metastatic breast tumors in mice, suggesting a new approach for treating bone-spreading breast cancers.
Researchers have identified a key cause of metastasis from aggressive brain cancer in children and found a potential new therapy. Medulloblastoma cells hijack neurodevelopmental signaling pathways to promote tumor cell spreading. Targeting these pathways with a drug called dasatinib has shown promise in killing metastatic tumors.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
Researchers have identified a new marker that indicates when skin cancer cells are preparing to metastasise. The study shows that tumour cells alter their metabolism to feed on bad cholesterol molecules, allowing them to survive migration and proliferation in other organs.
Researchers have identified markers associated with an increased risk of metastasis in patients with metastatic pheochromocytoma, allowing for personalized clinical management. The study also identifies patients who could benefit from immunotherapy treatments, paving the way for potential new therapies.
Researchers at Fred Hutchinson Cancer Center found that a protein secreted by cancer cells, angiopoietin-like-7, promotes tumor necrosis and metastasis in breast cancer. The study used a new rat model to investigate mechanisms of breast cancer metastasis and identified the protein as a potential target for treatment.
Researchers developed a new device that detects and analyzes cancer cells in blood samples, enabling doctors to avoid invasive biopsies and monitor treatment progress. The Static Droplet Microfluidic device uses metabolic signatures to differentiate tumour cells from normal blood cells.
Researchers re-examine molecular characteristics of WNT-subgroup patients to identify optimal treatment strategies for low-risk medulloblastoma. Key findings suggest that therapy-related late toxicity remains a concern, despite comparable survival rates between children and adolescents with this disease subtype.
Researchers have discovered a new mechanism of immune surveillance by liver-resident macrophages called Kupffer cells that prevent liver metastasis from escaping. They successfully cleared tumors in various animal models using a new method for in situ targeted expression and remodels of KCs' anti-tumor function.
A study finds that aggressive end-of-life care remains common among older adults with metastatic cancer, particularly in nursing home residents. Multilevel interventions targeting hospital admissions and in-hospital death are crucial to reducing its prevalence.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Researchers at NUS Cancer Science Institute discover FAM3C in tumor-derived extracellular vesicles promotes distant lung tumour colonization. FAM3C enhances cellular transformation and stimulates metastasis potential, offering new therapeutic strategy targets.
Researchers have developed a novel prognostic index to predict survival outcomes in gastric cancer patients. The inflammation-combined prognostic index (ICPI) combines three biomarkers - lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio - to provide a personalized prognosis for each patient.
Researchers at Helmholtz-Zentrum Dresden-Rossendorf developed a new strategy to increase target molecules for radionuclide therapy in pheochromocytoma tumors, delaying tumor growth. The combination of valproic acid and decitabine prior to therapy doubled the radiation dose absorbed by the tumor.
Researchers found that primary cancer tumors have a sluggish conversion of nutrients to usable cellular energy, conserving energy for growth and metastasis. The discovery has vast implications for anti-cancer strategies, directing attention to slow energy metabolism.
A new study published in Cell Reports Medicine identifies four pan-cancer molecular subtypes of metastasis, each with distinct transcriptional programs and potential therapeutic targets. The research provides valuable insights for personalized treatments of metastatic cancer.
A research team led by Professor Kwang-Hyun Cho at KAIST has developed a fundamental technology to revert metastatic lung cancer cells to a non-metastatic state. This breakthrough could lead to the elimination of drug resistance and metastatic potential in cancer cells, while increasing their responsiveness to chemotherapy.
A combination of two novel immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer. The study found that 23% of patients had a tumor reduction, and the disease control rate was 76%. The treatment was well-tolerated, but adverse events were common.
A Phase 3 clinical trial has shown that a four-drug chemotherapy regimen significantly increases overall survival and progression-free survival in patients with stage 4 pancreatic ductal adenocarcinoma. The study's results suggest that this more aggressive treatment approach may be considered for eligible patients.
Researchers at Bar-Ilan University have discovered a new molecular blocker that successfully halted breast cancer metastasis by targeting the Pyk2 and cortactin interaction. The study's findings provide significant hope for fighting breast cancer, as the blocker inhibited metastasis formation in breast cancer-bearing mice.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
Researchers identified a link between sphingolipids and complement signaling that regulates cancer cell migration and metastasis. High levels of S1P inside cancer cells activate the complement molecule C3, leading to inflammation-promoting complex formation and driving cancer spread.
A new study found that COVID-19 primarily affected patients with a moderate to critical course, often with comorbidities, whereas many had mild courses despite metastatic melanoma and systemic therapy, recommending continued treatment whenever possible.
Ringlike peripheral high iodine concentration maps from dual-energy CT can help guide management in patients with known lung cancer and an indeterminate solitary nodule. This finding showed excellent interobserver agreement, high specificity, and independently predicted pulmonary metastasis.
A new study has identified a protein called LAP1 that makes melanoma cells more aggressive by changing their nucleus shape. The protein allows cancer cells to migrate and spread throughout the body, leading to poor outcomes in patients.
The study found that methylation of the HLA-A gene and focal deletions resulted in reduced immune cell activity against cancer cells, leading to fewer immune cells being available to attack cancer cells. The researchers also discovered differences in immune cell response between various sites of metastasis.
PSMA PET/MRI successfully determines prostate cancer likelihood of return within two years after prostatectomy, aiding treatment decisions. High uptake in primary lesion and metastasis are associated with rapid recurrence.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
A study found that Medicare costs for metastatic prostate cancer increased significantly between 2007 and 2017, with average annual spending per patient rising from $28,311 to $37,055. The majority of the increase was attributed to new treatments under Medicare Part D, such as radium-223, sipuleucel-T, abiraterone, and enzalutamide.
A new AI-based predictive method has been created to detect radiotherapy failure in brain metastasis, showing an 83% accuracy rate compared to the human eye's 65%. The technique uses deep learning and attention mechanisms to analyze MRI images and provide more informed treatment decisions.
Researchers found that tumor cells directly interact with blood vessel cells, altering their normal clockwise orientation to a counterclockwise position. This interaction may play a role in cancer metastasis and could be targeted for prevention and treatment.
A new mechanism has been uncovered that enables cancer cells to move throughout the body, allowing them to spread and form metastases. This discovery provides a potential new target for stopping these deadly spreads, which are responsible for 90% of cancer deaths.
For adrenal lesions evaluated by single-phase dual-energy CT, fat fraction had significantly higher sensitivity than virtual noncontrast attenuation at both clinically optimal threshold and traditional ≤10 HU threshold. Fat fraction-derived metrics can help definitively diagnose incidental adrenal lesions as adenomas.
A new study suggests that blood tests can predict survival odds for patients with metastatic cancer by analyzing the proportion of tumor DNA in the bloodstream. Patients with higher levels of tumor DNA in their bloodstreams were found to have poorer survival rates across all cancer types studied.
Researchers at the Fred Hutchinson Cancer Center discovered that oral bacteria like Fusobacterium nucleatum can infiltrate tumors, influencing their growth and response to treatment. The findings suggest a link between oral health and cancer, highlighting the potential for microbiome-based therapies to combat cancer.
A study of 11,945 people found that those with type 2 diabetes are more likely to be diagnosed with advanced cancer if the condition is not screened for routinely. Researchers identified a 26% increased risk of metastasis in patients with pre-existing type 2 diabetes.
Research at Tel Aviv University found that high-intensity aerobic exercise increases glucose consumption in internal organs, reducing energy availability for tumors. The study reduced the risk of metastatic cancer in humans and animal models by up to 72%.
Researchers discovered that the Memo1 protein binds copper ions, blocking toxic redox reactions that damage or kill cancer cells. The protein's interaction with copper also protects against metastasis formation in breast cancer cells. This finding opens up potential new treatments for cancer.
Researchers found that oral cancer cells releasing EVs under TGF-β induce EndoMT in endothelial cells, leading to vascular destabilization. This process may facilitate cancer cell entry into the bloodstream, promoting metastasis.
A new treatment approach using surgery or radiation therapy has been shown to slow cancer progression in patients with solitary prostate cancer metastases. The study found that this approach, called metastasis-directed therapy (MDT), can delay the need for hormone-blocking treatments and improve survival rates.
Researchers at IRB Barcelona have identified the tiny fraction of tumour cells that remain hidden after surgery, leading to metastatic recurrence. These 'High Relapse Cells' can be eliminated through genetic techniques, preventing metastases and opening the possibility for new therapeutic strategies.
Researchers at Binghamton University discover that sodium/proton exchanger 1 (NHE1) and SWELL1 proteins regulate cancer cell migration, offering insights into metastasis. The study's findings could have wide implications for slowing down or halting the deadly disease.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.
Assistant Professor Nourridine Siewe developed a new mathematical model to assess different approaches for treating metastatic cancer. The model evaluates the interactions among immune cells and cancer, helping clinicians decide on the best treatment strategies.
A recent study found worsening disparities in cancer drug trial participant diversity from 2000 to 2018, highlighting systemic biases and unequal access to new treatments. The findings underscore the need for increased diversity in phase 1 clinical trials to ensure equitable access to life-saving treatments.
A recent study published in Oncotarget reveals that Nectin-4 is widely expressed in head and neck squamous cell carcinoma (HNSCC), with significant correlations to clinico-pathological parameters. Non-smokers and p16-positive HNSCC showed higher expression of Nectin-4, leading to better survival rates for positive tumors.
Researchers develop hybrid brightfield-darkfield transport of intensity approach, expanding accessible sample spatial frequencies and achieving 5-fold resolution increase. This method enables precise detection and quantitative analysis of subcellular features in large-scale cell studies.
Researchers found that cancer cells can migrate faster in higher viscosity environments due to the formation of denser actin networks and cooperative signaling pathways. This discovery provides a new framework for understanding metastasis and may lead to the identification of potential targets to combat cancer spread.